3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Status
Active not recruiting
2
Not yet recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
Conditions
Breast Neoplasms
10
Neoplasm Metastasis
4
Neoplasms by Site
3
Neoplasms
3
Breast Diseases
3
Advanced Breast Cancer
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Diseases
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
90
Blood Specimen Collection
41
Cyclophosphamide
37
Bevacizumab
36
Nivolumab
34
Standard of Care
32
Carboplatin
32
Surveys and Questionnaires
29
Paclitaxel
27
atezolizumab
25
Exercise
25
Pemetrexed
24
Cisplatin
24
Gemcitabine
23
Fluorouracil
22
Radiotherapy
20
Leucovorin
20
Dexamethasone
20
Oxaliplatin
18
Docetaxel
18
Rituximab
16
Irinotecan
16
Cetuximab
16
Drug Therapy
15
Doxorubicin
15
dostarlimab
14
Biopsy
14
130-nm albumin-bound paclitaxel
14
fludarabine
13
Prednisone
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Neoplasms
×
AZD9833
×
1 year
×
Clear all
NCT07647328
2026-06-15
SERAFA-1
AstraZeneca
Phase 3
Not yet recruiting
150 enrolled
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled
NCT04711252
2025-10-14
SERENA-4
AstraZeneca
Phase 3
Active not recruiting
1,370 enrolled